StockTipsArenaBeta

BUY Lupin Limited — Mehul Kothari, Anand Rathi

BUYLupin Limited

byMehul Kothari, Anand RathiHorizon: NA (inferred 1–3 months)21 Sept 2026via Zee Business (Live)

Entry₹2,109Inferred
Target₹2,300
Total upside +9.06%
Stop loss₹2,000-5.17% risk
CMP₹2,1354h ago
Active+1.23%+7.73%upside left 3 mo left
Follow Mehul Kothari for new calls(20% target hit, 20 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 4 other Short-term calls on LUPINSee 64 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Sept, 8:44 pm IST
9 supporting3 opposing
Supports the BUY call (9)

MACD above its signal line — bullish momentum

Technicals · macd·22 Sept · today

Lupin share price is currently 'overemphasizing' a risk while 'undermining' a positive, HSBC says

NewsCnbc-Tv18·22 Sept · today

(opens in new tab)

8 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·22 Sept · today

4 other SEBI-registered advisors have active short-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · same horizon·22 Sept · today

Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection

NewsGoogle News·16 Sept · 5d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (3)

Lupin share falls 2%; Citi downgrades to Sell, cuts target price to Rs 2,050

NewsEt-Markets·27 Aug · 4w ago

(opens in new tab)

Lupin share price: Citi downgrades, cuts target; Bernstein sees Kalydeco ruling as key positive

NewsCnbc-Tv18·27 Aug · 4w ago

(opens in new tab)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·27 Aug · 4w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.